- Home
- CRI vs EYPT Comparison
CRI vs EYPT Comparison
Compare CRI & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRI | EYPT |
|---|---|---|
| Founded | 1865 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2002 | 2005 |
Fundamental Metrics
Financial Performance| Metric | CRI | EYPT |
|---|---|---|
| Price | $35.17 | $13.77 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $34.00 | $31.80 |
| AVG Volume (30 Days) | 1.3M | ★ 1.4M |
| Earning Date | 04-24-2026 | 03-04-2026 |
| Dividend Yield | ★ 2.90% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.53 | N/A |
| Revenue | ★ $2,898,426,000.00 | $7,539,000.00 |
| Revenue This Year | $4.50 | N/A |
| Revenue Next Year | $0.92 | $1,031.72 |
| P/E Ratio | $13.63 | ★ N/A |
| Revenue Growth | ★ 1.91 | N/A |
| 52 Week Low | $23.38 | $3.91 |
| 52 Week High | $44.44 | $19.11 |
Technical Indicators
Market Signals| Indicator | CRI | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 45.37 | 41.29 |
| Support Level | $31.90 | $11.88 |
| Resistance Level | $39.05 | $14.24 |
| Average True Range (ATR) | 1.52 | 1.09 |
| MACD | -0.15 | -0.35 |
| Stochastic Oscillator | 70.46 | 14.91 |
Price Performance
Historical ComparisonAbout CRI Carter's Inc.
Carter's Inc makes apparel for babies and children under brand names including Carter's and OshKosh B'gosh. It sells its products through a multi-channel business model, which includes retail stores, eCommerce, and wholesale sales channels, as well as retail omnichannel capabilities in the United States and Canada, which enables it to reach a broad range of consumers around the world. The company operates in three segments; U.S. Retail, U.S. Wholesale, and International. The majority of revenue is derived from U.S. Wholesale segment. The company predominantly sources products through contract manufacturers in Asia. It has multiple distribution centers in the U.S., in addition to distribution centers in Canada and Asia that serve international customers.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.